Fundraising Fox

Ravgen

Columbia, US · Delaware corporation

Ravgen develops noninvasive prenatal genetic testing, using DNA-based methods to detect fetal genetic conditions such as Down's syndrome from a maternal blood sample. It serves pregnant patients seeking prenatal diagnostic information without the miscarriage risk of invasive procedures.

Founders & leadership

RD
Ravinder DhallanFounder, Chairman & CEO
KD
Kamlesh DhallanNamed on SEC filing
PB
Philip BaylissNamed on SEC filing
EM
Edward MotternNamed on SEC filing
ND
Narender DhallanNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$2.5M disclosed across 1 round · 2021

$2.5MraisedOct 2021 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kamlesh DhallanDirector
  • Philip BaylissDirector
  • Edward MotternDirector
  • Narender DhallanDirector
  • Ravinder DhallanExecutive Officer, Director, Promoter
Offering amount
$3.5M
Amount sold
$2.5M
First sale
May 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with Ravgen for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Ravgen do?
Ravgen develops noninvasive prenatal genetic testing, using DNA-based methods to detect fetal genetic conditions such as Down's syndrome from a maternal blood sample. It serves pregnant patients seeking prenatal diagnostic information without the miscarriage risk of invasive procedures.
Who founded Ravgen?
Ravgen was founded by Ravinder Dhallan.
How much funding has Ravgen raised?
Ravgen has disclosed $2.5M raised across 1 round.
Where is Ravgen headquartered?
Ravgen is headquartered in Columbia, US.